New CGM algorithm could simplify insulin dosing for diabetes

NCT ID NCT06111508

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tested a new computer algorithm that uses continuous glucose monitor (CGM) readings to automatically suggest the right dose of long-acting insulin for people with type 2 diabetes. Thirty adults already using basal insulin were followed for 18 weeks to see if the algorithm improved blood sugar control compared to standard self-monitoring. The goal was to increase the time blood sugar stays in a healthy range without causing dangerous lows.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Continuous glucose monitor (CGM) and degludec insulin
What this could lead to
If successful, this could lead to a simpler, more effective way for people with type 2 diabetes to manage their blood sugar using a CGM-based insulin dosing guide.
What could go wrong
This is a small, early pilot study with only 30 participants, so results may not apply to everyone. The algorithm may not improve blood sugar control more than standard methods.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Icahn School of Medicine at Mount Sinai

    New York, New York, 10029, United States

  • University of Virginia

    Charlottesville, Virginia, 22903, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.